Medical management of recurrent endometrioma with long-term norethindrone acetate
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
PURPOSE: Evaluate the efficacy of norethindrone acetate in the resolution of symptoms and regression of recurrent endometrioma. PATIENTS AND METHODS: Retrospective chart review at SUNY Downstate Medical Center of patients with a history of surgical excision of endometrioma (with histological confirmation) and recurrent endometrioma (demonstrated by strict sonographic criterion of endometrioma) who were willing to undergo follow-up. Patients were prescribed norethindrone acetate to be taken daily with follow-up sonograms until cysts regressed. Statistical analysis included Student's t-test and a simple linear regression model to assess cyst regression over time during treatment. RESULTS: Degree of pain was significantly lower on treatment when compared to baseline (P < 0.00001). Cyst size was significantly smaller in as little as 3 months (P < 0.0001). Average rate of regression with continuous treatment was 0.025 ± 0.015 cm/day. Total mean ± standard deviation regression time is 10.28 ± 8.25 months. CONCLUSION: Norethindrone acetate was effective in eradicating symptoms and producing complete regression of recurrent endometriomas. It should be considered for patients who are likely to adhere to a prolonged treatment regimen and comply with recommendations for surveillance with serial sonograms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eskenazi, B., & Warner, M. L. (1997) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70302-8 · Cited by 1,617
Donnez, J., Nisolle, M., Gillet, N., Smets, M., Bassil, S., & Casanas-Roux, F. (1996) · Human Reproduction · doi:10.1093/humrep/11.3.641 · Cited by 360
Recurrence of ovarian endometrioma after laparoscopic excision
Koga, K., Takemura, Y., Osuga, Y., Yoshino, O., Hirota, Y., Hirata, T., Morimoto, C., Harada, M., Yano, T., & Taketani, Y. (2006) · Human Reproduction · doi:10.1093/humrep/del125 · Cited by 203 · cited 1×
“In support of the theory that progesterone therapy may reduce recurrence rates are studies which show that pregnancy, a condition characterized by tonic elevations of serum progesterone, is protective in patients with prior resection of endometriomas.(24) Studies examining the efficacy of medical therapy for recurrent…”
Postoperative oral contraceptive exposure and risk of endometrioma recurrence
Vercellini, P., Somigliana, E., Daguati, R., Vigano, P., Meroni, F., & Crosignani, P. G. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.11.010 · Cited by 196
Recurrence of ovarian endometrioma after laparoscopic excision
Busacca, M., Marana, R., Caruana, P., Candiani, M., Muzii, L., Calia, C., & Bianchi, S. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70247-4 · Cited by 170 · cited 2×
“18 However, there is a relatively high recurrence rate of endometriomas (12%–30% after 2–5 years of follow-up), 19–25 which were treated primarily with conservative surgical management.”
Epidemiology of endometriosis in a Norwegian county
Moen, M. H., & Schei, B. (1997) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.3109/00016349709024584 · Cited by 154
Fedele, L., Bianchi, S., Zanconato, G., Berlanda, N., Raffaelli, R., & Fontana, E. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.08.028 · Cited by 97
Jee, B. C., Lee, J. Y., Suh, C. S., Kim, S. H., Choi, Y. M., & Moon, S. Y. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.11.027 · Cited by 79 · cited 2×
“Research shows that a 3-month course of a GnRH agonist or danazol had no impact on pelvic pain in women with stage III/IV endometriosis thus requiring a course of 6 months or more.(37,39,42) Treatment with aromatase inhibitors by Seal et al only reduced pelvic pain from severe (grades 8–10) to moderate (grades 3–4.”
Evidence-based management of endometrioma
Gelbaya, T. A., & Nardo, L. G. (2011) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2010.11.013 · Cited by 42
Cited by
Vercellini, P., Bracco, B., Mosconi, P., Roberto, A., Alberico, D., Dhouha, D., & Somigliana, E. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.11.016 · Cited by 127
Dienogest or Norethindrone acetate for the treatment of ovarian endometriomas: Can we avoid surgery?
Del Forno, S., Mabrouk, M., Arena, A., Mattioli, G., Giaquinto, I., Paradisi, R., & Seracchioli, R. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2019.04.010 · Cited by 88
A stepped-care approach to symptomatic endometriosis management: A participatory research initiative
Vercellini, P., Donati, A., Ottolini, F., Frassineti, A., Fiorini, J., Nebuloni, V., Frattaruolo, M. P., Roberto, A., Mosconi, P., & Somigliana, E. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.01.037 · Cited by 64
Dienogest in the treatment of endometriosis
Bizzarri, N., Remorgida, V., Leone Roberti Maggiore, U., Scala, C., Tafi, E., Ghirardi, V., Salvatore, S., Candiani, M., Venturini, P. L., & Ferrero, S. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.943734 · Cited by 63
Effect of Dienogest therapy on the size of the endometrioma
Vignali, M., Belloni, G. M., Pietropaolo, G., Barbasetti Di Prun, A., Barbera, V., Angioni, S., & Pino, I. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2020.1725965 · Cited by 50
Metadata
- Authors
- Muneyyirci-Delale, O.
- Venue
- International Journal of Women's Health
- Publisher
- Informa UK Limited
- Published
- 2012-03
- Volume
- 4
- Pages
- 149
- ISSN
- 1179-1411 (ISSN-L)
- OpenAlex
- W1995308824
- Cited by
- 29
- References
- 9
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medical management of recurrent endometrioma with long-term norethindrone acetate. https://app.cochat.ai/papers/10.2147/ijwh.s27819
- The paper
- Muneyyirci-Delale, O. (2012). Medical management of recurrent endometrioma with long-term norethindrone acetate. International Journal of Women's Health. https://doi.org/10.2147/ijwh.s27819
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.